Michael Andersson

17.2k citations

123 papers · 7.6k · 3 hit papers · h-index 37

Impact in

Cancer Research top 0.5%
- Breast Cancer Treatment Studies
Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology

Papers in

Oncology 72
- Cancer Treatment and Pharmacology 31
- HER2/EGFR in Cancer Research 30
- Cancer Risks and Factors 15
- Global Cancer Incidence and Screening 7
Cancer Research 39
- Breast Cancer Treatment Studies 34

Co-authors: Hans H. Storm (31 shared papers)Eero Pukkala (19 shared papers)Lois B. Travis (20 shared papers)Charles F. Lynch (14 shared papers)Eric J. Holowaty (12 shared papers)Mary Gospodarowicz (8 shared papers)Maj‐Britt Jensen (15 shared papers)Claus Kamby (7 shared papers)
Journals: Journal of Clinical Oncology (17 papers)JNCI Journal of the National Cancer Institute (10 papers)European Journal of Cancer (9 papers)Acta Oncologica (9 papers)Radiation Research (7 papers)
Partner nations: Denmark Sweden United States

In The Last Decade

Michael Andersson

121 papers receiving 7.4k citations

Michael Andersson's Hit Papers

align trajectories log scale

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study 2009 · 504 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Journal of Clinical Oncology
2005 JNCI Journal of the National Cancer Institute
1999 The Lancet

Peers

Countries citing papers authored by Michael Andersson

Since Specialization

Citations

This map shows the geographic impact of Michael Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Andersson more than expected).

Fields of papers citing papers by Michael Andersson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Andersson. The network helps show where Michael Andersson may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Andersson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Andersson Line = papers co-authored together Michael Andersson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 123 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial The Lancet ·Marie Overgaard, Maj‐Britt Jensen, Jens Overgaard, Per Syrak Hansen, Carsten Rose, Michael Andersson, Claus Kamby, Michael Kjær, C. Gadeberg, Birgitte Rasmussen, M Blichert-Toft, Henning T. Mouridsen Hit paper breakdown →	1999	1203
2	Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors JNCI Journal of the National Cancer Institute ·Lois B. Travis, Sophie D. Fosså, Sara J. Schonfeld, Mary L. McMaster, Charles F. Lynch, Hans H. Storm, Per Hall, Eric J. Holowaty, Aage Andersen, Eero Pukkala, Michael Andersson, Magnus Kaijser, Mary Gospodarowicz, Timo Joensuu, R.J. Cohen, John D. Boice, Graça M. Dores, Ethel S. Gilbert Hit paper breakdown →	2005	560
3	Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study Journal of Clinical Oncology ·Gϋnter von Minckwitz, Andreas du Bois, Marcus Schmidt, Nicolaì Maass, Tanja Čufer, Felix E. de Jongh, E. Maartense, Christoph Zielinski, Manfred Kaufmann, Wolfgang Bauer, Klaus Baumann, Michael Clemens, Ralph Duerr, Christoph Uleer, Michael Andersson, Robert C. Stein, Valentina Nekljudova, Sibylle Loibl Hit paper breakdown →	2009	504
4	Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease JAMA ·Lois B. Travis, Deirdre A. Hill, Graça M. Dores, Mary Gospodarowicz, Flora E. van Leeuwen, Eric J. Holowaty, Bengt Glimelius, Michael Andersson, Tom Wiklund, Charles F. Lynch, Mars B. vanʼt Veer, Ingrid Glimelius, Hans H. Storm, Eero Pukkala, Marilyn Stovall, Rochelle E. Curtis, John D. Boice, Ethel S. Gilbert	2003	457
5	Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin’s Disease: A Population-Based Evaluation Over 25 Years Journal of Clinical Oncology ·Graça M. Dores, Catherine Metayer, Rochelle E. Curtis, Charles F. Lynch, E. Aileen Clarke, Bengt Glimelius, Hans H. Storm, Eero Pukkala, Flora E. van Leeuwen, Eric J. Holowaty, Michael Andersson, Tom Wiklund, Timo Joensuu, Mars B. vanʼt Veer, Marilyn Stovall, Mary Gospodarowicz, Lois B. Travis	2002	404
6	Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer JNCI Journal of the National Cancer Institute ·L. B. Travis, Rochelle E. Curtis, Joseph F. Fraumeni, John D. Boice, Hans H. Storm, Michael Andersson, Per Hall, Kjell Bergfeldt, Eric J. Holowaty, E. Aileen Clarke, Flora E. van Leeuwen, Betsy Kohler, Eero Pukkala, Tom Wiklund, G Stoter, Mary Gospodarowicz, Jeremy Sturgeon	1997	348
7	Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer New England Journal of Medicine ·Lois B. Travis, Eric J. Holowaty, Kjell Bergfeldt, Charles F. Lynch, Betsy Kohler, Tom Wiklund, Rochelle E. Curtis, Per Hall, Michael Andersson, Eero Pukkala, Jeremy Sturgeon, Hans H. Storm, E. Aileen Clarke, John D. Boice, Mary Gospodarowicz, Marilyn Stovall	1999	256
8	Second Cancers Among 104760 Survivors of Cervical Cancer: Evaluation of Long-Term Risk JNCI Journal of the National Cancer Institute ·Anil K. Chaturvedi, Eric A. Engels, Ethel S. Gilbert, Bingshu E. Chen, Hans H. Storm, Charles F. Lynch, Per Hall, Frøydis Langmark, Eero Pukkala, Magnus Kaijser, Michael Andersson, Sophie D. Fosså, Heikki Joensuu, John D. Boice, Ruth A. Kleinerman, Lois B. Travis	2007	249
9	Second Cancers Among Long-Term Survivors of Hodgkin’s Disease Diagnosed in Childhood and Adolescence Journal of Clinical Oncology ·Catherine Metayer, Charles F. Lynch, E. Aileen Clarke, Bengt Glimelius, Hans H. Storm, Eero Pukkala, Timo Joensuu, Flora E. van Leeuwen, Mars B. vanʼt Veer, Rochelle E. Curtis, Eric J. Holowaty, Michael Andersson, Tom Wiklund, Mary Gospodarowicz, Lois B. Travis	2000	242
10	Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma Journal of Clinical Oncology ·David Hodgson, Ethel S. Gilbert, Graça M. Dores, Sara J. Schonfeld, Charles F. Lynch, Hans H. Storm, Per Hall, Frøydis Langmark, Eero Pukkala, Michael Andersson, Magnus Kaijser, Heikki Joensuu, Sophie D. Fosså, Lois B. Travis	2007	237
11	Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study Journal of Clinical Oncology ·Michael Andersson, Elisabeth Lidbrink, Karsten Bjerre, Erik Wist, Kristin Enevoldsen, Anders Bonde Jensen, Per Karlsson, Ulla Brix Tange, Peter G. Sørensen, Susanne Möller, Jonas Bergh, Sven Tyge Langkjer	2010	213
12	Lung Cancer after Treatment for Hodgkin's Disease: Focus on Radiation Effects Radiation Research ·E. S. Gilbert, Marilyn Stovall, Mary Gospodarowicz, F. E. van Leeuwen, Michael Andersson, Bengt Glimelius, Timo Joensuu, C. F. Lynch, R. E. Curtis, Eric J. Holowaty, Hans H. Storm, Eero Pukkala, M. B. van't Veer, J F Fraumeni, John D. Boice, E. Aileen Clarke, L. B. Travis	2003	157
13	Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer European Journal of Cancer ·Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt, Jana Barinoff, Christoph Mundhenke, Tanja Čufer, E. Maartense, Felix E. de Jongh, Klaus Baumann, Joachim Bischoff, Nadia Harbeck, Hans‐Joachim Lück, Nicolaì Maass, Christoph Zielinski, Michael Andersson, Robert C. Stein, Valentina Nekljudova, Sibylle Loibl	2011	141
14	Noncancer Causes of Death in Survivors of Testicular Cancer JNCI Journal of the National Cancer Institute ·Sophie D. Fosså, Ethel S. Gilbert, Graça M. Dores, Jinbo Chen, Katherine A. McGlynn, Sara J. Schonfeld, Hans H. Storm, Per Hall, Eric J. Holowaty, Aage Andersen, Heikki Joensuu, Michael Andersson, Magnus Kaijser, Mary Gospodarowicz, R.J. Cohen, Eero Pukkala, Lois B. Travis	2007	132
15	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial Breast Cancer Research and Treatment ·Evandro de Azambuja, Worta McCaskill‐Stevens, Prudence A. Francis, Emmanuel Quinaux, John Crown, Malou Vicente, Rosa Giuliani, Bo Nordenskjöld, Jorge Gutiérez, Michael Andersson, Mireia Margelí Vila, R. Jakesz, Jan Demol, Joanna Dewar, Armando Santoro, Aňa Lluch, Steven R. Olsen, Richard D. Gelber, Angelo Di Leo, Martine Piccart	2009	128
16	Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial JNCI Journal of the National Cancer Institute ·Prudence A. Francis, John Crown, Angelo Di Leo, Marc Buyse, A. Balil, Michael Andersson, Bo Nordenskjöld, István Láng, R. Jakesz, D. Vorobiof, J. Gutiérrez, Guy van Hazel, Stella Dolci, Soazik P. Jamin, Belguendouz Bendahmane, Richard D. Gelber, A. Goldhirsch, Monica Castiglione‐Gertsch, Martine Piccart, (unknown)	2008	111
17	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial Journal of Clinical Oncology ·Amir Sonnenblick, Dominique Agbor‐Tarh, Ian Bradbury, Serena Di Cosimo, Hatem A. Azim, Debora Fumagalli, Séverine Sarp, Antonio C. Wolff, Michael Andersson, Judith R. Kroep, Tanja Čufer, Sérgio D. Simon, Pamela Salman, Masakazu Toi, Lyndsay N. Harris, Julie R. Gralow, Maccon Keane, Alvaro Moreno‐Aspitia, Martine Piccart, Evandro de Azambuja	2017	106
18	PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab Annals of Oncology ·Jeanette Dupont Jensen, Ann Knoop, Anne‐Vibeke Lænkholm, Morten Grauslund, Maj‐Britt Jensen, Eric Santoni‐Rugiu, Michael Andersson, Marianne Ewertz	2011	106
19	Checkpoint inhibitors in breast cancer – Current status Cancer Treatment Reviews ·Anne Dyhl-Polk, Inge Marie Svane, Michael Andersson, Dorte Nielsen	2017	106
20	HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors Cancer Treatment Reviews ·Dorte Nielsen, Michael Andersson, Claus Kamby	2008	96

About Michael Andersson

Michael Andersson is a scholar working on Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 123 papers that have together received 7.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (34 papers), Cancer Treatment and Pharmacology (31 papers), HER2/EGFR in Cancer Research (30 papers), Cancer Risks and Factors (15 papers), Monoclonal and Polyclonal Antibodies Research (11 papers), Radiation Dose and Imaging (8 papers), Global Cancer Incidence and Screening (7 papers) and Advanced Breast Cancer Therapies (7 papers). The work is most often cited by research in Cancer Research (2.2k citations), Oncology (3.2k citations), Pathology and Forensic Medicine (1.6k citations), Radiation (505 citations) and Radiology, Nuclear Medicine and Imaging (1.3k citations). Michael Andersson has collaborated with scholars based in Denmark, Sweden and United States. Frequent co-authors include Hans H. Storm, Eero Pukkala, Lois B. Travis, Charles F. Lynch, Eric J. Holowaty, Mary Gospodarowicz, Maj‐Britt Jensen, Claus Kamby, Per Hall and Henning T. Mouridsen. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, European Journal of Cancer, Acta Oncologica and Radiation Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Michael Andersson

Impact in

Papers in i

In The Last Decade

Michael Andersson

Michael Andersson's Hit Papers

Peers

Countries citing papers authored by Michael Andersson

Fields of papers citing papers by Michael Andersson

All Works

About Michael Andersson

Explore authors with similar magnitude of impact

Papers in